drugset / Trial / NCT00561197

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197

Phase 1/2 Terminated 13 enrolled Ascenta Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.

Timeline

Start
2007-08
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AT-101 Small molecule 10 mg
Background Docetaxel Small molecule 20 mg/m2 Intravenous
Background fluorouracil Small molecule 300 mg/m2